InvestorsHub Logo
Followers 124
Posts 12252
Boards Moderated 0
Alias Born 11/08/2021

Re: HyGro post# 531884

Monday, 11/14/2022 11:11:27 AM

Monday, November 14, 2022 11:11:27 AM

Post# of 705894

the post hoc totally redone clinical trial design is enough to raise serious questions


False. As linked here many times, this was not done 'post hoc' but before the trial was unblinded. This has been confirmed in presentations written or presented by Dr. Mulholland, Dr. Ashkan and Dr. Liau.

Add the confounding of the naive OS (double dosing)



False. The only confounding is that NWBO allowed crossovers to take DCVax-L. There is no confounding in counting beating hearts. I've linked relevant SEC filings multiple times. In fact, the FDA REQUIRED the crossover option.

regulators are going to have serious issues



False, the MHRA approved pediatric trials using the same design.

There are lots of false narratives out there on social media. It is important people do their own research.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News